Hay R J, Logan R A, Moore M K, Midgely G, Clayton Y M
Mycology Unit, St. Thomas Hospital, London, U.K.
J Am Acad Dermatol. 1991 Feb;24(2 Pt 1):243-6. doi: 10.1016/0190-9622(91)70035-z.
We conducted a double-blind comparative study of terbinafine, 250 mg twice daily, versus griseofulvin, 500 mg twice daily, for 6 weeks in chronic dermatophyte infections of the feet or hands. All but three patients (total 31) had Trichophyton rubrum infection. At 12-week follow-up, 100% of the terbinafine-treated group were free from infection compared with 45% of those treated with griseofulvin. Therapy in 75% of the terbinafine-treated group and in 35% of those given griseofulvin was rated as effective overall at long-term follow-up, although these differences were not statistically significant. Six months after treatment all nine patients whose skin had cleared with terbinafine therapy remained in remission versus only one of seven patients treated with griseofulvin. None of the patients in either group experienced serious adverse effects.
我们进行了一项双盲对照研究，比较每日两次服用250毫克特比萘芬与每日两次服用500毫克灰黄霉素，治疗手足慢性皮肤癣菌感染6周的疗效。除3名患者（共31名）外，其余患者均感染红色毛癣菌。在12周的随访中，特比萘芬治疗组100%无感染，而灰黄霉素治疗组为45%。在长期随访中，特比萘芬治疗组75%的患者和灰黄霉素治疗组35%的患者治疗总体评定为有效，尽管这些差异无统计学意义。治疗6个月后，特比萘芬治疗皮肤已清除的9名患者均仍处于缓解状态，而灰黄霉素治疗的7名患者中只有1名仍处于缓解状态。两组患者均未出现严重不良反应。
